Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

CL in Medical Oncology

Dr Lennard Lee

Pathway to a Clinical Lectureship

I graduated from the University of Cambridge in 2005 and studied clinical medicine at the University of Oxford.

I was successfully awarded a Medical Research Council Clinical Training Research Fellowship in 2013 with Professor Ian Tomlinson at the Wellcome Trust Centre for Human Genetics. I then took on a role as a BRC Clinical Research Training Fellow with Prof David Kerr.

In 2018, I was recruited to the Institute of Cancer and Genomic Sciences, University of Birmingham as a Senior Clinical Training Research Fellow.

In 2020, I was recruited to Oxford University as an academic clinical lecturer. 

What has the work involved?

I started my work at the University of Oxford in August 2020. My research is on metastatic colorectal cancer. However, since COVID-19, an increasing amount of my work is supporting Oxford University’s major COVID-19 research programs.

As a result of my success with the UK Coronavirus Cancer Monitoring Project, I was selected to help develop Oxford University’s mass testing research programs. The Falcon-MoonShot study, where I was project delivery lead, was launched in 3 days and brought about practice change in 40 days.

These projects have enabled me to develop skills working and leading large research consortia and bringing about rapid clinical change.

As a result of the successful programs, I am currently on secondment to the Department of Health and Social Care to deliver other UK priority COVID-19 projects.


Oxford University is a wonderful research institution to work in. There are an incredible number of very talented individuals working in the institution and we have shown ourselves adaptive and incredibly responsive to priority research areas.

An example of this is the incredible progress that Oxford has pioneered in vaccine development, mass testing and clinical trials for hospital patients with COVID-19, in addition to our incredible progress with cancer therapies.

To date, I have had the incredible experience of working alongside some incredible academics, like Prof Derrick Crook and Prof Tim Peto. In August, when I started, access to COVID-19 testing was being severely limited. However, as a result of our work, Oxford has helped establish the paradigm of mass and this has identified thousands of additional COVID-19 cases.

My experience has opened my eyes to the ability to be part of, and lead, genuinely practice changing research programs and the ability to deliver clinical benefit at pace. My experience will help make cancer clinical trials even more dynamic in future. 

August 2020